Smiths Group plc Amends ICU Medical Stake Filing

TL;DR

Smiths Group updated its ICU Medical filing on 3/1/24. Keep an eye on this.

AI Summary

Smiths Group plc, through its subsidiary Smiths Group International Holdings Ltd, has amended its Schedule 13D filing regarding ICU Medical, Inc. The filing, dated March 1, 2024, indicates a change in beneficial ownership. Smiths Group plc is headquartered in London, UK, and ICU Medical, Inc. is based in San Clemente, CA.

Why It Matters

This amendment to a Schedule 13D filing signals a potential shift in the ownership structure or strategy of ICU Medical, Inc., which could impact its stock price and future business decisions.

Risk Assessment

Risk Level: medium — Schedule 13D filings often precede significant corporate actions like mergers, acquisitions, or activist investor campaigns, introducing uncertainty.

Key Numbers

• 0000883984 — ICU Medical CIK (Central Index Key for ICU Medical, Inc.)
• 0001326143 — Smiths Group CIK (Central Index Key for Smiths Group plc)

Key Players & Entities

• Smiths Group plc (company) — Filing entity
• Smiths Group International Holdings Ltd (company) — Subsidiary of Smiths Group plc
• ICU Medical, Inc. (company) — Subject company
• Matthew Whyte (person) — Person authorized to receive notices
• White & Case LLP (company) — Legal counsel

FAQ

Key Financial Figures

• $0.10 — me of Issuer) Common Stock, par value $0.10 per share (Title of Class of Securitie
• $106.075 — ecuted by a broker-dealer at a price of $106.075 per share of Common Stock. As a result

Filing Documents

• ea0201043-13da1smiths_icu.htm (SC 13D/A) — 50KB
• ea0201043ex99-1_icumedical.htm (EX-99.1) — 5KB
• ea0201043ex99-2_icumedical.htm (EX-99.2) — 4KB
• 0001213900-24-019011.txt ( ) — 61KB

of the Schedule 13D is hereby amended and supplemented as follows

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On February 29, 2024, Shareholder sold 830,000 shares of Common Stock held by it in accordance with the Form 144 that was filed by the Shareholder on the same day. The shares of Common Stock were sold through a trade order executed by a broker-dealer at a price of $106.075 per share of Common Stock. As a result of these sales, Shareholder now owns 1,670,000 shares of Common Stock. Item 5. Interest in Securities of the Issuer. (a) - (b) The information relating to the beneficial by reference herein. The percentages set forth in Row 13 for all cover pages filed herewith are calculated based upon 24,142,564 shares of Common Stock outstanding as of January 31, 2024, as reported in the Issuer’s 10-K. Smiths Group may be deemed to have beneficial Persons share power to vote or to direct the vote of and power to dispose or to direct the disposition of such 1,670,000 shares of Common Stock. (c) On February 29, 2024, Shareholder sold 830,000 shares of Common Stock held by it in accordance with the Form 144 that was filed by the Shareholder on the same day. The shares of Common Stock were sold through a trade order executed by a broker-dealer at a price of $106.075 per share of Common Stock. The aforementioned transaction is the only transaction in the Common Stock by the Reporting Persons in the sixty days preceding the date of this Amendment, or since the most recent filing of Schedule 13D by the Reporting Persons, whichever is less. (d) No person is known to the Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any securities covere

View Full Filing

View this SC 13D/A filing on SEC EDGAR